Veradermics
MANE | NYSE
$134.13
-$5.56 (-3.98%)
Nov 2, 2026, 11:43 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q4 2024 Dec 31, 2024 |
|---|---|---|---|---|---|
Net Income | -92.68M | -69.18M | -41.95M | -25.76M | -5.66M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a |
Stock-Based Compensation | 9.89M | 6.37M | 1.11M | 229K | 91K |
Other Working Capital | -872K | -829K | -3.63M | -1.09M | -199K |
Other Non-Cash Items | 6.33M | 792K | 238K | 1.49M | 1.09M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | -1.83M | -1.79M | -2.04M | 1.4M | 844K |
Operating Cash Flow | -78.3M | -63.81M | -42.64M | -22.65M | -3.63M |
Capital Expenditures | -26K | -5K | -5K | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -242.78M | -242.78M | -119.79M | n/a | n/a |
Sales Maturities Of Investments | 46.71M | 46.71M | 25.02M | 15M | n/a |
Other Investing Acitivies | -277.27M | n/a | n/a | n/a | n/a |
Investing Cash Flow | -473.36M | -196.08M | -94.78M | 15M | n/a |
Debt Repayment | n/a | n/a | n/a | -2.51M | -2.51M |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 442.25M | -447K | -447K | 767K | -283K |
Financial Cash Flow | 862.4M | 419.7M | 150.59M | 51.38M | 50.31M |
Net Cash Flow | 310.74M | 159.82M | 13.17M | 43.74M | 46.67M |
Free Cash Flow | -78.33M | -63.82M | -42.65M | -22.65M | -3.63M |
Adj. Free Cash Flow | -88.21M | -70.19M | -43.76M | -22.88M | -3.72M |
Maintenance CapEx | n/a | n/a | n/a | n/a | n/a |
Growth CapEx | -26K | -5K | n/a | n/a | n/a |
Owner Earnings | -78.3M | -67.44M | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove MANE